Cardiac surgery is associated with significant mortality rates. Careful selection of surgical
candidates is, therefore, vital to optimize morbidity and mortality outcomes. Risk scores can …

Background: The STICH trial (Surgical Treatment for Ischemic Heart Failure) demonstrated a
survival benefit of coronary artery bypass grafting in patients with ischemic cardiomyopathy …

Abstract Introduction The Charlson Comorbidity Index (CCI) is widely utilized for risk
stratification by providers, payors, and administrative database researchers for non-cardiac …

Objective: To evaluate meaningful, patient-centered outcomes including alive-at-home
status and patient-reported quality of life 1 year after cardiac surgery. Background: Long …

Cardiac surgery results in a multifactorial systemic inflammatory response with inflammatory
cytokines, such as interleukin-10 and 6 (IL-10 and IL-6), shown to have potential in the …

Objective Several short‐term readmission and mortality prediction models have been
developed using clinical risk factors or biomarkers among patients undergoing coronary …

Background We tested the potential of the Secondary Manifestations of Arterial Disease
(SMART2) risk score for use in patients undergoing coronary artery bypass grafting …

Background Cardiac biomarkers soluble ST-2 (sST-2) and N-terminal prohormone B-type
natriuretic peptide (NT-proBNP) may be associated with long-term survival after cardiac …

Abstract Introduction The Charlson Comorbidity Index (CCI) is widely utilized for risk
stratification for non-cardiac surgical patients, yet it has not been broadly validated in …

Background Galectin-3 (Gal-3) is a well-established biomarker of adverse clinical outcomes,
but its prognostic value for long-term survival after cardiac surgery is not well understood …